

June 10, 2022



# Trevena to Participate at the JMP Securities Life Sciences Conference

CHESTERBROOK, Pa., June 10, 2022 (GLOBE NEWSWIRE) -- **Trevena, Inc. (Nasdaq: TRVN)**, a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO, and Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference being held in New York on June 15 - 16, 2022.

## *Fireside Chat Details*

Date: Wednesday, June 15, 2022

Time: 10:00am ET

[Webcast Link](#)

A link to the webcast will be available on the Events page of the Investors section of the Company's website at <https://www.trevena.com/investors/events-presentations/ir-calendar>

A replay of the presentation will be archived on the website and available for approximately 30 days following the event. Please contact your JMP Securities representative to schedule virtual one-on-one meetings with Trevena during the conference.

## **About Trevena**

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVIK<sup>®</sup> (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company's novel pipeline is based on Nobel Prize winning research and includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder.

For more information, please visit [www.Trevena.com](http://www.Trevena.com)

## **Forward-Looking Statements**

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development and trials of its therapeutic candidates and approved product, plans for potential future product candidates and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "suggest," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute

forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the status, timing, costs, results and interpretation of the Company's clinical trials or any future trials of any of the Company's investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company's assessment of discussions with FDA; available funding; uncertainties related to the Company's intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company's therapeutic candidates and approved product; and other factors discussed in the Risk Factors set forth in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.

**For more information, please contact:**

**Investor Contact:**

Dan Ferry  
Managing Director  
LifeSci Advisors, LLC  
daniel@lifesciadvisors.com  
(617) 430-7576

**PR & Media Contact:**

Sasha Bennett  
Associate Vice President  
Clyde Group  
Sasha.Bennett@clydegroupp.com  
(239) 248-3409

**Company Contact:**

Bob Yoder  
SVP and Chief Business Officer  
Trevena, Inc.  
(610) 354-8840



Source: Trevena, Inc.